ReviewLife (Basel, Switzerland)2021
Influencing Factors and Molecular Pathogenesis of Sarcopenia and Osteosarcopenia in Chronic Liver Disease.
Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Covert hepatic encephalopathy in cirrhosis: implications for early diagnosis and appropriate management.Clinical journal of gastroenterology · 2026Review
- Sarcopenia Is Associated with Altered Rocuronium Onset and Neuromuscular Blockade Kinetics in Liver Transplant Recipients: A Prospective Observational Cohort Study.Journal of clinical medicine · 2026Article
- Osteosarcopenia, Osteoporosis, and Sarcopenia in Liver Cirrhosis: Prevalence, Predictors, and Prognostic Significance of IGF-1 Deficiency.Journal of clinical medicine · 2026Article
- Association of Sarcopenia and Bone Mineral Density in Patients with Chronic Liver Disease: A Prospective Cohort Study Using Standardised Scales.Juntendo medical journal · 2026Article
- Bioelectrical impedance analysis-derived phase angle predicts osteosarcopenia and mortality in patients with chronic liver disease.Scientific reports · 2025Article
- Osteosarcopenia in metabolic dysfunction-associated steatotic liver disease: from mechanisms to management.Frontiers in endocrinology · 2025Review
- Sarcopenia in liver transplantation: A comprehensive bibliometric study of current research trends and future directions.Open life sciences · 2025Article
- Osteosarcopenia: epidemiology, molecular mechanisms, and management.Frontiers in endocrinology · 2025Review
- Low geriatric nutritional risk index is associated with osteoporosis and fracture risk in patients with chronic liver disease: a cross-sectional study.BMC gastroenterology · 2024Article
- Prediction of Osteoporotic Hip Fracture Outcome: Comparative Accuracy of 27 Immune-Inflammatory-Metabolic Markers and Related Conceptual Issues.Journal of clinical medicine · 2024Article
- Association of chronic liver disease with bone diseases and muscle weakness.Journal of bone and mineral metabolism · 2024Review
- A Prognostic Model Based on Nutritional Indexes for Patients With Pan-Cancer: A Real-World Cohort Study.Cancer reports (Hoboken, N.J.) · 2024Article
- Prevalence of osteosarcopenia and its association with mortality and fractures among patients undergoing hemodialysis.Journal of bone and mineral metabolism · 2024Article
- PIVKA‑II is associated with liver function, bone metabolism, and muscle function in patients with liver disease.Biomedical reports · 2024Article
- What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?Life (Basel, Switzerland) · 2023Review
- Sex-Specific Associations between Serum IL-16 Levels and Sarcopenia in Older Adults.Nutrients · 2023Article
- Sarcopenic Obesity in People with Alcoholic Use Disorder: Relation with Inflammation, Vascular Risk Factors and Serum Vitamin D Levels.International journal of molecular sciences · 2023Article
- Osteosarcopenia predicts poor survival in patients with cirrhosis: a retrospective study.BMC gastroenterology · 2023Article
- Prognostic significance of sarcopenia and severe vitamin D deficiency in patients with cirrhosis.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- The Geriatric Nutritional Risk Index predicts sarcopenia in patients with cirrhosis.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver plays a pivotal role in nutrient/energy metabolism and storage, anabolic hormone regulation, ammonia detoxification, and cytokine production. Impaired liver function can cause malnutrition, hyperammonemia, and chronic inflammation, leading to an imbalance between muscle protein synthesis and proteolysis. Patients with chronic liver disease (CLD) have a high prevalence of sarcopenia, characterized by progressive loss of muscle mass and function, affecting health-related quality of life and prognosis. Recent reports have revealed that osteosarcopenia, defined as the concomitant occurrence of sarcopenia and osteoporosis, is also highly prevalent in patients with CLD. Since the differentiation and growth of muscles and bones are closely interrelated through mechanical and biochemical communication, sarcopenia and osteoporosis often progress concurrently and affect each other. Osteosarcopenia further exacerbates unfavorable health outcomes, such as vertebral fracture and frailty. Therefore, a comprehensive assessment of sarcopenia, osteoporosis, and osteosarcopenia, and an understanding of the pathogenic mechanisms involving the liver, bones, and muscles, are important for prevention and treatment. This review summarizes the molecular mechanisms of sarcopenia and osteosarcopenia elucidated to data in hopes of promoting advances in treating these musculoskeletal disorders in patients with CLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.